Foghorn Therapeutics Inc.
FHTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.26 | 0.42 | -0.18 |
| FCF Yield | -39.10% | -44.08% | 72.51% | -6.30% |
| EV / EBITDA | -2.48 | -2.25 | 0.25 | -8.39 |
| Quality | ||||
| ROIC | -43.67% | -46.11% | -146.40% | -21.16% |
| Gross Margin | 100.00% | -221.15% | 99.90% | -469.75% |
| Cash Conversion Ratio | 1.16 | 1.20 | -1.78 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.54% | 195.85% | 254.94% | – |
| Free Cash Flow Growth | 15.10% | -162.02% | 459.21% | -12.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 0.34 | 2.59 | 0.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -52.85 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -442.80 | -20.83 | -102,772.52 | 82,831.95 |